RARE Ultragenyx
Company Analysis
Latest News
🟢 Ultragenyx is trading 13.99% up in pre-market after FDA granted accelerated approval for GENGLYCOS
Ultragenyx is trading 13.99% up at $29.91 after FDA granted accelerated approval for GENGLYCOS on August 19, 2026. - GENGLYCOS treats glycogen storage disease...
Ultragenyx Receives FDA Accelerated Approval for GSDIa Gene Therapy GENGLYCOS™
Ultragenyx Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for its gene therapy, GENGLYCOS™...
🟢 Ultragenyx is trading 10% up in after-hours trading with no verified company-specific catalyst
Ultragenyx is trading 10% up at $28.86 after closing at $26.24 on August 19, 2026, with no verified company-specific announcement released after the regular...
🔴 Ultragenyx is trading 4.1% down today as higher yields pressure biotech stocks
Ultragenyx is trading 4.1% down now at $25.07, primarily as higher yields and broader risk-off trading pressure growth-oriented biotechnology stocks. - No...
Ultragenyx Settles DOJOLVI® Patent Litigation, Allows Generic Entry in 2033
Ultragenyx Pharmaceutical Inc. has entered into a settlement agreement with Esjay Pharma to resolve patent litigation related to its drug, DOJOLVI®...
🟢 Ultragenyx is trading 4% up today after record Q2 results beat estimates
Ultragenyx is trading 4.01% up now at $26.95 after investors continued reacting to its record second-quarter results. - Q2 revenue reached $214 million,...
Ultragenyx Posts Its Best Quarter Ever, But Can a Still-Unprofitable Biotech Turn a Revenue Beat Into a Real Turnaround?
Shares of Ultragenyx Pharmaceutical shifted sharply higher after the rare-disease drugmaker delivered a blowout second quarter that caught Wall Street off...
Ultragenyx Posts Its Best Quarter Ever, But Can a Still-Unprofitable Biotech Turn a Revenue Beat Into a Real Turnaround?
Shares of Ultragenyx Pharmaceutical shifted sharply higher after the rare-disease drugmaker delivered a blowout second quarter that caught Wall Street off...
🟢 Ultragenyx is trading 4.6% up today after record Q2 revenue beat
Ultragenyx is trading 4.6% up now at $26.07 after investors continued reacting to its August 4 earnings release and record second-quarter revenue. -...
🔴 Ultragenyx is trading 4.1% down today on post-earnings profit-taking
Ultragenyx is trading 4.1% down at $24.77 today as the stock undergoes a typical post-earnings reversal following yesterday's significant rally. • The company...
🟢 Ultragenyx is trading 4.1% up today after record Q2 revenue and earnings beat
Ultragenyx is trading 4.1% up at $25.57 after reporting record second-quarter revenue that significantly exceeded Wall Street expectations. • The company...
🟢 Ultragenyx is trading 6.4% up today after record Q2 revenue and earnings beat
Ultragenyx is trading 6.4% up at $27.47 in pre-market sessions after reporting record second-quarter revenue and a narrower-than-expected net loss per...
🟢 Ultragenyx is trading 6.4% up today after reporting record Q2 revenue and a narrowed net loss
Ultragenyx is trading at $27.46 (6.4% up) after reporting record second-quarter revenue of $214 million, which exceeded consensus estimates and narrowed its...
Ultragenyx reports record second quarter revenue of $214M, beating estimates and reaffirming its FY2026 outlook.
Ultragenyx Pharmaceutical announced record revenue for its second quarter, surpassing analyst expectations on both revenue and earnings per share. The company...
🟢 Ultragenyx is trading 4.1% up today ahead of Q2 earnings and pipeline updates
Ultragenyx is trading 4.1% up at $26.04 as investors position ahead of the company’s second-quarter 2026 earnings report scheduled for August 04, 2026. •...
Ultragenyx Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Analysts anticipate a Q2 2026 loss of $1.27 per share on revenue of $182.5 million, with the current stock price of $52.42 significantly trailing the consensus...
🔴 Ultragenyx is trading 4.5% down today amid a broader biotech sector pullback
Ultragenyx is trading 4.5% down today at $24.86 following a broader pullback in the biotechnology sector. • The move appears driven by risk-off sentiment...
🟢 Ultragenyx is trading 4.3% up today amid broad market strength and biotech sector gains
Ultragenyx is trading at $26.07 (up 4.3%) amid a broad risk-on move in U.S. equities and strength in biotech peers. • The stock appears to be rebounding from...
🔴 Ultragenyx is trading 4.2% down today tracking broader biotech and macro weakness
Ultragenyx is trading at $24.88 (-4.23%) as the stock faces pressure amid a broader biotech risk-off tone and general market weakness. • No fresh...
🔴 Ultragenyx is trading 4.2% down today with no clear company-specific catalyst
Ultragenyx is trading 4.2% down today at $25.92 as the stock faces individual pressure despite a supportive backdrop for the broader biotech industry. • No...